In his Société Internationale d’Urologie (SIU) lecture “What are we aiming at? Balancing costs or optimal clinical efficacy for intervention in BPH”, Prof. Damien Bolton (University of Melbourne, Australia) said, “While TURP has and probably will remain the benchmark in terms of metrics, voiding flow, and International Prostate Symptom Score (IPSS) result, it does not tell the whole story.”
Treating BPH with drugs vs surgery has demonstrated substantial reduced costs, can be associated with less patient morbidity, and can delay definitive treatment if necessary or desired. Prof. Bolton stated that even though symptomatic improvement might be suboptimal, it is acceptable to most patients as they prioritise quality of life over their flow rate.
Prof. Bolton postulated that minimally invasive surgical techniques must compete against pharmacotherapy to demonstrate advantages and to become the established standard of care. Until robust prospective data ar...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Office Urology Next Article
St. Gallen Consensus – Adjuvant Therapy in Triple-negative Breast Cancer »
Table of Contents: EAU 2019
Renal Transplantation and Renal Cell Carcinoma
Lower Urinary Tract Symptoms
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.